Drugs
Genentech, Inc. (DNA), Biogen Idec, Inc. (BIIB), and Roche (SWX) have completed the filing of a supplemental biologics license application (sBLA) with the U.S. Food and Drug Administration (FDA) for an additional indication of Rituxan (Rituximab) in previously untreated patients with intermediate-grade or aggressive, CD-20-positive, B-cell, non-Hodgkin lymphoma (NHL)
Pharmaceutical industry
As a pioneer in direct-to-consumer (DTC) advertising, Amgen has announced its commitment to upholding the Pharmaceutical Research and Manufacturers of America's (PhRMA) Guiding Principles on DTC advertising. By signing onto these voluntary principles, Amgen recognizes the potential of DTC advertising to increase awareness about diseases, educate patients about
Pharmaceutical industry
ICOS Corporation and its joint venture Lilly ICOS LLC reported financial results for the second quarter of 2005, with Lilly ICOS nearing profitability due to increased sales and reduced marketing expenses. The company launched a Phase 3 clinical study for the treatment of pulmonary arterial hypertension using tadalafil, the active
Drugs
Orion Genomics has initiated partnerships with renowned researchers at Washington University in St. Louis, Missouri, to discover novel biomarkers for early cancer detection. The collaborations aim to identify "Second Code" biomarkers, which include DNA methylation patterns that indicate the presence of cancer and its responsiveness to certain therapies.
Drugs
Corautus Genetics, a clinical-stage biopharmaceutical company, has reported an update on its therapeutic development program and financial results for the three and six months ended June 30, 2005. The company's GENASIS clinical trial is the largest cardiovascular study of its kind, evaluating the safety and efficacy of vascular
Drugs
The partnership between NeoRx Corporation (NERX) and The Scripps Research Institute marks the first collaboration at Scripps Florida, focusing on the discovery of novel, small-molecule, multitargeted, protein kinase inhibitors as therapeutic agents, including cancer treatments. This research alliance will be supported by a $2.5 million grant from NeoRx over
Drugs
Acorda Therapeutics has strengthened its senior leadership with two key additions: Gerard A. Cignarella as Vice President of Business Development and Herbert Henney III, PharmD, as Vice President of Medical Affairs. Cignarella brings a rich background in marketing and business development, having previously worked at Pfizer and Regions Limited Incorporated.
Drugs
VNUS Medical Technologies, Inc., a pioneer in medical devices for treating venous reflux disease, has become a member of the Nasdaq Health Care Index, announced on July 27, 2005. As one of the initial companies to join this index, VNUS is part of a list of 545 companies that meet
Drugs
AutoGenomics, Inc., and Targeted Molecular Diagnostics, Inc., have formed a 3-year development partnership to create novel cancer biomarkers for oncology. The collaboration will leverage the AutoGenomics INFINITI platform to develop tests for pharmaceutical and biotech companies, which will aid in the preclinical and clinical development of targeted therapies. The first
Biotechnology industries
Genzyme Corp. announced a strong second quarter 2005, with revenue increasing 22% to $668.1 million from $549.6 million in the same quarter last year. The company's non-GAAP net income rose 46% to $149.0 million, and non-GAAP earnings per diluted share increased to $0.57 from
Biotechnology industries
HepaLife Technologies, Inc. (HPLF) has entered into an agreement with Fusion Capital Fund II, LLC to raise up to $15 million in equity financing. The agreement allows HPLF to sell newly issued stock to Fusion Capital in monthly installments of up to $500,000 over a period of up to
Biotechnology industries
Morphotek, Inc., a biotechnology company focused on developing optimized therapeutic antibodies, has strengthened its partnership with Baxter Healthcare Corporation by broadening their manufacturing supply agreement. This move will enable Morphotek to secure a steady supply of its lead compounds, including MORAb-003, which is currently in phase I clinical trials for
